Walleye Capital LLC grew its stake in shares of Amyris, Inc. (NASDAQ:AMRS – Get Rating) by 65.4% during the second quarter, HoldingsChannel reports. The firm owned 87,297 shares of the biotechnology company’s stock after purchasing an additional 34,513 shares during the quarter. Walleye Capital LLC’s holdings in Amyris were worth $161,000 at the end of the most recent quarter.
A number of other large investors have also recently modified their holdings of AMRS. Daiwa Securities Group Inc. boosted its stake in shares of Amyris by 11.1% during the 1st quarter. Daiwa Securities Group Inc. now owns 250,000 shares of the biotechnology company’s stock valued at $1,090,000 after purchasing an additional 25,000 shares in the last quarter. Cookson Peirce & Co. Inc. bought a new stake in Amyris during the first quarter worth about $703,000. Envestnet Asset Management Inc. boosted its stake in Amyris by 59.8% during the first quarter. Envestnet Asset Management Inc. now owns 237,281 shares of the biotechnology company’s stock worth $1,035,000 after acquiring an additional 88,791 shares in the last quarter. Commonwealth Equity Services LLC bought a new stake in Amyris during the first quarter worth about $95,000. Finally, Prospera Financial Services Inc bought a new stake in Amyris during the first quarter worth about $39,000. Institutional investors own 43.08% of the company’s stock.
Amyris Stock Performance
Shares of Amyris stock opened at $2.22 on Friday. The stock has a market capitalization of $721.92 million, a PE ratio of -1.28 and a beta of 1.22. Amyris, Inc. has a 52-week low of $1.44 and a 52-week high of $7.39. The company has a 50-day simple moving average of $2.82 and a two-hundred day simple moving average of $2.55.
Insiders Place Their Bets
Analysts Set New Price Targets
AMRS has been the topic of several research reports. Oppenheimer lowered shares of Amyris from an “outperform” rating to a “market perform” rating in a research note on Wednesday, November 9th. Roth Capital lowered shares of Amyris from a “buy” rating to a “neutral” rating in a research note on Wednesday, August 10th. Cowen dropped their price objective on shares of Amyris from $13.00 to $6.00 in a research note on Thursday, November 10th. JPMorgan Chase & Co. cut shares of Amyris from an “overweight” rating to a “neutral” rating in a report on Thursday, November 10th. Finally, Piper Sandler lifted their target price on shares of Amyris from $2.50 to $4.00 and gave the stock a “neutral” rating in a report on Monday, September 19th. One analyst has rated the stock with a sell rating and four have given a hold rating to the stock. According to MarketBeat, Amyris has an average rating of “Hold” and a consensus price target of $5.33.
Amyris, Inc, a synthetic biotechnology company, operates in the clean health and beauty, and flavors and fragrance markets in Europe, North America, Asia, and South America. The company manufactures and sells clean beauty, personal care, and health and wellness consumer products, as well as ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets.
- Get a free copy of the StockNews.com research report on Amyris (AMRS)
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
- Does ASML’s November Rally Have Staying Power?
- Verra Mobility Stock Has Returned Back to the Station
Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.